EGFR and non-small cell lung carcinoma: Together, the above data revealed that the treatment of EGFR inhibitors could suppress the αvβ3− tumor cells proliferation and drive the integrin αvβ3+ cells accumulation, leading to EGFR inhibitors resistance in NSCLC.